ArticlemSystems2025
Multidrug-resistant
Article in mSystems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Prognostic factors and predictive modeling of in-hospital mortality among MDRO-positive inpatients: a retrospective cohort and GBD MICROBE study.Antonie van Leeuwenhoek · 2026Article
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Multiphase terminal environmental disinfection targeting Acinetobacter baumannii sustains reduction in multidrug-resistant organism healthcare-associated infections in an ICU.Antimicrobial resistance and infection control · 2026Article
- Clinical risk factors for multidrug-resistant organism infections in postoperative gastric cancer patients: an ICU-based retrospective analysis.BMC infectious diseases · 2026Article
- Thyme and cinnamon essential oils inhibit multidrug resistant Escherichia coli and Klebsiella pneumoniae and alter virulence transcripts.Scientific reports · 2026Article
- Genomic Characterization of Antimicrobial Resistance and Virulence in ST11 Carbapenem-ResistantInfection and drug resistance · 2026Article
- Risk Factors and Medical Burden of Multidrug-Resistant Organism Infection in Hospitalized Patients with Pneumonia.Infection and drug resistance · 2026Article
- Risk factors, resistance profiles, and clinical outcomes ofFrontiers in cellular and infection microbiology · 2026Article
- Synergistic Interactions Between Natural Phenolic Compounds and Antibiotics Against Multidrug-ResistantMicroorganisms · 2025Article
- The potential of the microbiome as a target for prevention and treatment of carbapenem-resistant Enterobacteriaceae infections.Frontiers in cellular and infection microbiology · 2025Review
- Investigation of the susceptibility rates to ceftazidime-avibactam and colistin, clonal relationships, and clinical data of patients with carbapenem-resistantAnnals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The prevalence of multidrug-resistant IMPORTANCE: Coinfections and carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.